Spaulding Clinical Research Expands Clinical Pharmacology Facility With 12-Bed First-In-Human, High-Visibility Unit
Spaulding Clinical Research, a change agent in the clinical research and medical device industries, announced that the company has completed a First-In-Human (FIH) study using their dedicated, 12-bed FIH High-Visibility-Unit (HVU). The study was conducted for a biotech Sponsor developing a non-opioid analgesic.
"Subject safety is our primary consideration in conducting any Clinical Pharmacology study. As part of our commitment to safety, we designed the High-Visibility-Unit for First-in-Human studies or any study where the compound requires added surveillance or very intensive monitoring, "states Daniel Selness, General Manager and Sr. Vice President of Clinical Research at Spaulding.
The study Sponsor stated this was an "ideal place to conduct this study" and was very impressed with the operational flow, as well as the entire infrastructure supporting the HVU including backup power, and close proximity to required processing areas. The unit is staffed by ACLS-certified research staff who are well-trained on the emergency response plan and equipment.
Spaulding's decentralized study approach, where all dosing, blood draws and procedures are performed at the bedside, translates efficiently into the 12-bed, HVU with glass sliding doors and a glass-enclosed central nursing station. Clinical investigators and study staff can view subjects in their rooms from the nursing station, as well as monitor their 12-lead ECGs, pulse oximetry and vital signs continuously. All study data is fully integrated into a customized Clinical Pharmacology Electronic Data Capture (EDC) solution which can be remotely viewed by the study Sponsor in real-time.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
